ダウンロード数: 34
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.jjcc.2022.03.015.pdf | 678.38 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Nishimoto, Yuji | en |
dc.contributor.author | Yachi, Sen | en |
dc.contributor.author | Takeyama, Makoto | en |
dc.contributor.author | Tsujino, Ichizo | en |
dc.contributor.author | Nakamura, Junichi | en |
dc.contributor.author | Yamamoto, Naoto | en |
dc.contributor.author | Nakata, Hiroko | en |
dc.contributor.author | Ikeda, Satoshi | en |
dc.contributor.author | Umetsu, Michihisa | en |
dc.contributor.author | Aikawa, Shizu | en |
dc.contributor.author | Hayashi, Hiroya | en |
dc.contributor.author | Satokawa, Hirono | en |
dc.contributor.author | Okuno, Yoshinori | en |
dc.contributor.author | Iwata, Eriko | en |
dc.contributor.author | Ogihara, Yoshito | en |
dc.contributor.author | Ikeda, Nobutaka | en |
dc.contributor.author | Kondo, Akane | en |
dc.contributor.author | Iwai, Takehisa | en |
dc.contributor.author | Yamada, Norikazu | en |
dc.contributor.author | Ogawa, Tomohiro | en |
dc.contributor.author | Kobayashi, Takao | en |
dc.contributor.author | Mo, Makoto | en |
dc.contributor.author | Yamashita, Yugo | en |
dc.contributor.alternative | 奥野, 善教 | ja |
dc.contributor.alternative | 山下, 侑吾 | ja |
dc.date.accessioned | 2023-05-16T01:55:58Z | - |
dc.date.available | 2023-05-16T01:55:58Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.uri | http://hdl.handle.net/2433/282103 | - |
dc.description.abstract | BACKGROUND: Data on thrombosis and current real-world management strategies for anticoagulation therapy are scarce but important for understanding current issues and unmet needs of an optimal management of patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021, and we tried to capture the status of the patients in the fourth and fifth waves of the COVID-19 infections in Japan. We enrolled consecutive hospitalized patients who were diagnosed with COVID-19 and had a positive polymerase chain reaction test obtained from the hospital databases. RESULTS: Among 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in 9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. The types and doses of anticoagulants varied widely across the participating centers. During the hospitalization, 38 patients (1.3%) and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrast-enhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism (71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4% with moderate COVID-19, and 9.5% with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia. CONCLUSIONS: In the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19. | en |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | en |
dc.publisher | Japanese College of Cardiology | en |
dc.rights | © 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. | en |
dc.rights | This is an open access article under the CC BY-NC-ND license. | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.subject | Coronavirus disease 2019 | en |
dc.subject | Thrombosis | en |
dc.subject | Anticoagulants | en |
dc.subject | Asian | en |
dc.subject | Japan | en |
dc.title | The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | Journal of Cardiology | en |
dc.identifier.volume | 80 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 285 | - |
dc.identifier.epage | 291 | - |
dc.relation.doi | 10.1016/j.jjcc.2022.03.015 | - |
dc.textversion | publisher | - |
dc.identifier.pmid | 35430141 | - |
dcterms.accessRights | open access | - |
dc.identifier.pissn | 0914-5087 | - |
dc.identifier.eissn | 1876-4738 | - |
出現コレクション: | 学術雑誌掲載論文等 |
このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス